Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
After losing a fight over access to millions of seized documents, Fortescue has settled its trade secrets case against green iron company Element Zero.
Andrew ‘Twiggy’ Forrest’s Fortescue can’t get access to nine million seized documents in its trade secrets spat against green iron start-up Element Zero.
J&J-owned Janssen Pharmaceutica has sued Juno Pharmaceuticals, alleging the Australian off-patent drug maker is threatening to infringe its patent for a schizophrenia drug by seeking to list its own products on the PBS.
Nike has lost its challenge to a Canberra AFL club’s trade mark, with IP Australia finding that the “arc-like feature” depicting a football in flight was not deceptively similar to the sportswear giant’s iconic swoosh mark.
IP boutique Davies Collison Cave has brought proceedings against its Melbourne landlord at the Orica House, seeking a declaration that it has not abandoned its lease.
Puma has appealed its failed opposition to a trade mark for Tiger Woods’ golf apparel and equipment brand Sun Day Red, which the German sneaker giant argued was too similar to its iconic leaping cat mark.
Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Green iron startup Element Zero is challenging a bid by Fortescue for access to nine million seized documents in their trade secrets spat, saying its rival has not met the test for proving inadequate discovery of material.